Riociguat
From HOP house of papers
(Difference between revisions)
Ossip Groth (Talk | contribs) m (→Article Collections) |
Ossip Groth (Talk | contribs) m (→Some trials) |
||
| (2 intermediate revisions by one user not shown) | |||
| Line 52: | Line 52: | ||
{{tp|p=23775260|t=2013. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study |pdf=http://circ.ahajournals.org/content/128/5/502.full.pdf|usr=}} | {{tp|p=23775260|t=2013. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study |pdf=http://circ.ahajournals.org/content/128/5/502.full.pdf|usr=}} | ||
{{tp|p=C4565564|t=2015. Bioavailability, pharmacokinetics and safety of riociguat given as an oral suspension or crushed tablet with and without food |pdf=|usr=}} | {{tp|p=C4565564|t=2015. Bioavailability, pharmacokinetics and safety of riociguat given as an oral suspension or crushed tablet with and without food |pdf=|usr=}} | ||
| + | {{tp|p=C4565089|t=2015. The sGC-stimulator Riociguat for the treatment of Raynaud s phenomenon: A single-dose, double-blind, randomized, placebo-controlled cross-over study (DIGIT) |pdf=|usr=}} | ||
| Line 63: | Line 64: | ||
==Article Collections== | ==Article Collections== | ||
| − | {{slink|l=http://www.moremed.org/MedlineBsuchtPMC.php?Q=%28BMC+Pharmacol+Toxicol%5BJOUR%5D+AND+16%5BVI%5D+AND+Suppl%201%5BIP%5D%29&Z0=0&ZL=150&Y=&MTB=1&px1=proxy.nationallizenzen.de&px2=&px3=&px4= |Congress Abstracts on Guanylate Cyclase | + | {{slink|l=http://www.moremed.org/MedlineBsuchtPMC.php?Q=%28BMC+Pharmacol+Toxicol%5BJOUR%5D+AND+16%5BVI%5D+AND+Suppl%201%5BIP%5D%29&Z0=0&ZL=150&Y=&MTB=1&px1=proxy.nationallizenzen.de&px2=&px3=&px4= |t=Congress Abstracts on Guanylate Cyclase Stimulation 2015 '''Abstracts from the 7th International Conference on cGMP Generators, Effectors and Therapeutic Implications'''|c= }} |
==Links== | ==Links== | ||
Latest revision as of 20:16, 2 February 2016
| search term via moremed.org ' |
| Riociguat |
Contents |
Core OA papers on Riociguat
| Journal article, free access |
| GET 2014. Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Extract PDF direct |
| Journal article, free access |
| GET 2015. Riociguat: Something new in pulmonary hypertension therapeutics? Extract PDF direct |
| Journal article, free access |
| GET 2014. Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Extract PDF direct |
| Journal article, free access |
| GET 2013. Riociguat for the treatment of pulmonary arterial hypertension Extract PDF direct |
| Journal article, free access |
| GET 2013. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension Extract PDF direct |
| Journal article, free access |
| GET 2010. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study Extract PDF direct |
| Journal Paper, restricted access |
| GET 2014. Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension Extract PDF direct |
General outline of Pulmonary Hypertension
| Journal article, free access |
| GET 2013. Recent progress in the diagnosis and management of chronic thromboembolic pulmonary hypertension Extract PDF direct |
| Journal article, free access |
| GET 2015. Medical treatment update on pulmonary arterial hypertension Extract PDF direct |
| Journal article, free access |
| GET 2015. The molecular targets of approved treatments for pulmonary arterial hypertension Extract PDF direct |
| Journal article, free access |
| GET 2015. Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension Extract PDF direct |
| Journal article, free access |
| GET 2014. Drug Therapy for Chronic Thromboembolic Pulmonary Hypertension: A Review of the Comparative Clinical Effectiveness Extract PDF direct |
| Journal article, free access |
| GET 2014. Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Chronic thromboembolic pulmonary hypertension Extract PDF direct |
| Journal article, free access |
| GET 2014. Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and surgical management for pulmonary arterial hypertension Extract PDF direct |
| Journal article, free access |
| GET 2013. Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow? Extract PDF direct |
| Journal article, free access |
| GET 2014. Respiratory review of 2014: pulmonary thromboembolism Extract PDF direct |
| Journal article, free access |
| GET 2014. Novel and emerging therapies for pulmonary hypertension Extract PDF direct |
| Journal article, free access |
| GET 2013. Chronic thromboembolic pulmonary hypertension: role of medical therapy Extract PDF direct |
| Journal Paper, restricted access |
| GET 2015. Pulmonary arterial hypertension: a review in pharmacotherapy Extract PDF direct |
Mechanism of action
| Journal article, free access |
| GET 2010. Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension? Extract PDF direct |
| Journal article, free access |
| GET 2009. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy Extract PDF direct |
| Journal article, free access |
| GET 2008. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension Extract PDF direct |
| Journal Paper, restricted access |
| GET 2013. The chemistry and biology of soluble guanylate cyclase stimulators and activators Extract PDF direct |
| Journal Paper, restricted access |
| GET 2009. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension Extract PDF direct |
| Journal Paper, restricted access |
| GET 2013. Soluble guanylate cyclase stimulators in pulmonary hypertension Extract PDF direct |
| Journal Paper, restricted access |
| GET 2009. NO-independent, haem-dependent soluble guanylate cyclase stimulators Extract [{| class="wikitable"; style="border: 1pt" |
| Journal Paper, restricted access |
| GET 2013. Soluble guanylate cyclase stimulators in pulmonary hypertension Extract PDF direct |
|}
Some trials
| Journal Paper, restricted access |
| GET 2015. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2) Extract PDF direct |
| Journal Paper, restricted access |
| GET 2015. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2) Extract PDF direct |
| Journal article, free access |
| GET 2014. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study Extract PDF direct |
| Journal article, free access |
| GET 2014. Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema Extract PDF direct |
| Journal article, free access |
| GET 2015. Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease Extract PDF direct |
| Journal article, free access |
| GET 2015. Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Extract PDF direct |
| Journal article, free access |
| GET 2013. Treatment of pulmonary hypertension caused by left heart failure with pulmonary arterial hypertension-specific therapies: lessons from the right and LEPHT Extract PDF direct |
| Journal article, free access |
| GET 2013. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study Extract PDF direct |
| Journal article, free access |
| GET 2015. Bioavailability, pharmacokinetics and safety of riociguat given as an oral suspension or crushed tablet with and without food Extract [ PDF direct] |
| Journal article, free access |
| GET 2015. The sGC-stimulator Riociguat for the treatment of Raynaud s phenomenon: A single-dose, double-blind, randomized, placebo-controlled cross-over study (DIGIT) Extract [ PDF direct] |
| Journal Paper, restricted access |
| GET 2013. The cyclic GMP-dependent protein kinase Ialpha suppresses kidney fibrosis Extract PDF direct |
| Journal Paper, restricted access |
| GET 2015. Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies Extract PDF direct |
| Journal article, free access |
| GET 2015. Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence Extract PDF direct |
| Journal article, free access |
| GET 2011. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats Extract PDF direct |
| Journal Paper, restricted access |
| GET 2010. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models Extract PDF direct |
Article Collections
| Weblink noncommercial ' |
| Congress Abstracts on Guanylate Cyclase Stimulation 2015 Abstracts from the 7th International Conference on cGMP Generators, Effectors and Therapeutic Implications |
Links
| Weblink noncommercial ' |
| Heise-Technol-Rev. Bericht zur Ehrung der Entwickler |
| Wikipedia |
| en-wiki |
| de-wiki |
Books
